Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6610919 | 1.00 | USP2 (0.58) | USP2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL6807845 | 0.84 | USP2 (0.67) | USP2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL6807842 | 0.84 | USP2 (0.67) | USP2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL6805485 | 0.79 | DNMT1 (0.60) | USP2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL6612362 | 0.79 | DNMT1 (0.60) | USP2KMT2AMEN1MAPTKDM4E | |
| SCHEMBL6809131 | 0.72 | APP (0.63) | APP | |
| SCHEMBL6615318 | 0.72 | APP (0.63) | APP | |
| SCHEMBL6611986 | 0.70 | TYR (0.58) | — | |
| SCHEMBL6801744 | 0.70 | TYR (0.58) | — | |
| SCHEMBL6809399 | 0.70 | APP (0.76) | APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | claimed |
| US-20040132807-A1 | Aurones as telomerase inhibitors | PHARMACIA ITALIA SPA (IT) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132807-A1 | Aurones as telomerase inhibitors | TERT, TERF2, TERF2IP | USP2 2117/4885KMT2A 828/4885MEN1 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.